cancer immunotherapy Archives
Apr. 1, 2021—Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment
Jan. 7, 2019—GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
Mar. 12, 2018—Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.